Mersana Therapeutics Inc

NASDAQ:MRSNUnited States

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.

Contact Information

Headquarters

840 Memorial DrCAMBRIDGE, MA, United States 02139-3789

Phone

617-498-0020

Fax

302-655-5049

Executives

Independent Chairman of the Board

David Mott

President, Chief Executive Officer, Director

Martin Huber

Chief Financial Officer, Chief Operating Officer, Senior Vice President

Brian Deschuytner

Senior Vice President, Chief Science and Technology Officer

Timothy Lowinger

Senior Vice President, Chief Development Officer

Mohan Bala